Results on DUPIXENT® (Dupilumab) from NOTUS Phase 3 COPD Trial Published in NEJM

On 20 May 2024, Regeneron and Sanofi announced the results of the NOTUS Phase 3 trial for use of  Dupixent® (dupilumab) as a maintenance treatment in adults with uncontrolled COPD and type 2 inflammation. The results were published in the New England Journal of Medicine on 21 May 2024 and reportedly demonstrate that Dupixent reduced exacerbations by 34% and improved lung function compared to placebo.   Previously, on 13 May 2024, Regeneron and Sanofi announced that the FDA accepted for priority review their sBLA for Dupixent® for adolescents with Chronic Rhinosinusitis with Nasal Polyposis (CRSwNP).